Racing Moderna, Pfizer starts phase 3 trial of mRNA flu vaccine

Pfizer has begun a phase 3 clinical trial of its mRNA-based influenza vaccine, keeping it tucked in behind Moderna in the race to upend the seasonal flu market using the technology that defined the response to COVID-19.